05/20/2025
4:24 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/20/2025
3:48 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
SAUNDERS BRENT L (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/20/2025
3:50 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Fitzpatrick Alexander A (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/14/2025
6:01 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2025
6:03 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/02/2025
7:05 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/08/2025
3:45 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/07/2025
1:26 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/24/2025
6:57 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Flynn James E (Filed by)
| Form SCHEDULE 13D/A | |
03/21/2025
5:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/20/2025
3:03 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for SBTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
03/20/2025
3:05 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/20/2025
6:02 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/20/2025
6:04 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/07/2025
4:12 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/05/2025
4:18 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/05/2025
4:19 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025
3:35 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/03/2025
11:06 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/31/2025
4:21 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form S-3ASR | |
01/13/2025
7:08 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/07/2025
5:24 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/06/2025
3:36 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/19/2024
3:20 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/19/2024
3:20 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:52 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:53 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
4:24 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/12/2024
4:41 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/12/2024
4:02 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2024
5:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
5:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
4:31 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Dorsey Brian (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
3:48 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
10:15 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/09/2024
4:43 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
4:25 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
11:38 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144/A | |
12/06/2024
6:15 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2024
4:30 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/05/2024
4:06 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Elon’s BIGGEST warning yet? (Ad) Tesla's About to Prove Everyone Wrong... Again
Back in 2018, when Jeff Brown told everyone to buy Tesla…
The "experts" said Elon was finished and Tesla was headed for bankruptcy.
Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again. |
12/03/2024
4:25 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
6:01 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
5:22 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
3:42 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/27/2024
3:11 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/15/2024
2:21 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/13/2024
7:16 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting)
Deerfield Mgmt III, L.P. (Reporting)
Deerfield Mgmt IV, L.P. (Reporting)
Deerfield Private Design Fund III, L.P. (Reporting)
Deerfield Private Design Fund IV, L.P. (Reporting)
Flynn James E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/13/2024
6:02 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/13/2024
6:00 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/17/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/16/2024
3:01 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
10:28 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
6:02 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/10/2024
3:27 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
3:28 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/23/2024
3:15 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/19/2024
3:26 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:29 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
3:06 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
3:24 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
3:25 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/10/2024
9:31 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/28/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:41 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:38 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VI LLC (Reporting)
ORBIMED CAPITAL LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:43 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
ORBIMED CAPITAL LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/21/2024
5:47 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:48 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:49 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
3:18 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/12/2024
6:59 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/18/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
11:07 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/11/2024
4:03 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2024
4:04 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
2:15 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2024
5:46 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/24/2024
4:06 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dadoo Rajeev (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/24/2024
4:13 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Trump’s Exec Order #14154 could be a “Millionaire-Maker” (Ad) Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.”
We recently sat down with Rickards to capture all the key details on tape.
 For the moment, you can watch this interview free of charge – just click here. |
06/21/2024
4:00 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
7:47 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Pratik Shah Living Trust dated June 15, 2011 (Filed by)
| Form SC 13D/A | |
06/17/2024
5:39 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/13/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
